Search

Your search keyword '"Segala, Daniela"' showing total 28 results
Start Over Author "Segala, Daniela"
28 results on '"Segala, Daniela"'

1. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Author

Ziviani, Luigi, Malescio, Feliciana, Turrini, Irene, Lawlor, Rita, Romano, Annamaria, Nunziata, Mariagrazia, Armato, Salvatore, Mazzeo, Nicole, Carleo, Maria Aurora, Dell’Isola, Chiara, Pisapia, Raffaella, Pontarelli, Agostina, Olivani, Andrea, Grasselli, Sara, Laccabue, Diletta, Leoni, Maria Cristina, Paolillo, Franco, Mancini, Annalisa, Ruaro, Barbara, Confalonieri, Marco, Salton, Francesco, Mancarella, Giulia, Marocco, Raffaella, De Masi, Margherita, Belvisi, Valeria, Lamonica, Silvia, Cingolani, Antonella, Seguiti, Cristina, Brambilla, Paola, Ferraresi, Alice, Lupi, Matteo, Ludovisi, Serena, Renisi, Giulia, Massafra, Roberta, Pellicciotta, Martina, Armiento, Luciana, Vimercati, Stefania, Piacenza, Mariagrazia, Bonfanti, Paolo, Columpsi, Paola, Cazzaniga, Marina Elena, Rovelli, Cristina, Ceresini, Mariaelena, Previtali, Letizia, Trentini, Laura, Alcantarini, Chiara, Rugge, Walter, Biffi, Stefano, Poletti, Federica, Rostagno, Roberto, Moglia, Roberta, De Negri, Ferdinando, Fini, Elisabetta, Cangialosi, Alice, Bruno, Serena Rita, Rizzo, Marianna, Niglio, Mariangela, Stritto, Anna Dello, Matano, Alfredo, Petruzziello, Arnolfo, Valsecchi, Pietro, Pieri, Teresa, Altamura, Mauro, Calamo, Angela, Giannelli, Anna, Menolascina, Stefania, Di Bari, Silvia, Mauro, Vera, Aronica, Raissa, Segala, Daniela, Cultrera, Rosario, Sighinolfi, Laura, Abbott, Michelle, Gizzi, Andrea, Marascia, Federica Guida, Valenti, Giacomo, Feasi, Marcello, Bobbio, Nicoletta, Del Puente, Filippo, Nicosia, Alfredo, Frascà, Martina, Mazzoleni, Miriam, Garofalo, Nadia, Ammendola, Virginia, Grazioli, Fabiana, Napolitano, Federico, Vitelli, Alessandra, Marcellini, Valentina, Capone, Stefania, Fusco, Francesco M., Milleri, Stefano, Borrè, Silvio, Carbonara, Sergio, Lo Caputo, Sergio, Leone, Sebastiano, Gori, Giovanni, Maggi, Paolo, Cascio, Antonio, Lichtner, Miriam, Cauda, Roberto, Dal Zoppo, Sarah, Cossu, Maria V., Gori, Andrea, Roda, Silvia, Confalonieri, Paola, Bonora, Stefano, Missale, Gabriele, Codeluppi, Mauro, Mezzaroma, Ivano, Capici, Serena, Pontali, Emanuele, Libanore, Marco, Diani, Augusta, Lanini, Simone, Battella, Simone, Contino, Alessandra M., Piano Mortari, Eva, Genova, Francesco, Parente, Gessica, Dragonetti, Rosella, Colloca, Stefano, Visani, Luigi, Iannacone, Claudio, Carsetti, Rita, Folgori, Antonella, and Camerini, Roberto

Published
2023
Full Text
View/download PDF

3. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients With HIV/HCV Coinfection: Results of an Italian Compassionate Use Program

Author

SIMIT (Società Italiana di Malattie Infettivee Tropicali), Andreoni, Massimo, Teti, Elisabetta, Antinori, Andrea, Milazzoi, Laura, Sollima, Savatore, Rizzardini, Giuliano, Di Biagio, Antonio, Saracino, Annalisa, Bruno, Raffaele, Borghi, Vanni, De Luca, Andrea, Cattelan, Annamaria, Hasson, Hamid, Taliani, Gloria, Monforte, Antonella D'Arminio, Mastroianni, Claudio Maria, Di Perri, Giovanni, Bigoni, Sara, Puoti, Massimo, Spinetti, Angiola, Gori, Andrea, Boffa, Nicola, Cacopardo, Bruno, Giacometti, Andrea, Parruti, Giustino, Vullo, Vincenzo, Chirianni, Antonio, Pennica, Alfredo, Pasquazzi, Caterina, Segala, Daniela, and Sarmati, Loredana

Published
2017

4. Visits to Sexually Transmitted Infection Clinics in Italy from January 2016 to November 2021: A Multicenter, Retrospective Study

Author

Borghi, Alessandro, primary, Flacco, Maria Elena, additional, Pacetti, Lucrezia, additional, Orioni, Gionathan, additional, Marzola, Elisa, additional, Cultrera, Rosario, additional, Guerra, Valentina, additional, Manfredini, Roberto, additional, Gaspari, Valeria, additional, Segala, Daniela, additional, and Corazza, Monica, additional

Published
2023
Full Text
View/download PDF

5. Correlates of Treatment and Disease Burden in People Living with HIV (PLHIV) in Italy

Author

Cingolani, Antonella, Tavelli, Alessandro, Maggiolo, Franco, Perziano, Annalisa, Saracino, Annalisa, Vichi, Francesca, Cernuschi, Massimo, Guaraldi, Giovanni, Quiros-Roldan, Eugenia, Castagna, Antonella, Antinori, Andrea, d’Arminio Monforte, Antonella, Segala, Daniela, Cingolani, A., Tavelli, A., Maggiolo, F., Perziano, A., Saracino, A., Vichi, F., Cernuschi, M., Guaraldi, G., Quiros-Roldan, E., Castagna, A., Antinori, A., and Monforte, A. D.

Subjects
Antiretroviral, HIV, Long acting, Treatment burden, Medicine, General Medicine, treatment burden, antiretroviral, long actin, long acting, Article, NO
Abstract

Treatment burden is a multidimensional concept, including several aspects of life of patients affected by chronic conditions. It has been poorly explored in people living with HIV (PLHIV). An online anonymous survey of PLHIV taking antiretroviral therapy (ART) was conducted, in order to investigate the self-reported correlates of disease burden. HIV Treatment and Diseases Burden (TDB) was investigated with a questionnaire containing 31 items in 7 domains. Respondents were stratified in high burden (H-TDB)/low burden (L-TDB) according to overall HIV TDB mean + 1 standard deviation. Factors associated with H-TDB has been evaluated with a logistic regression model. In total, 531 PLHIV completed the questionnaire. 99 PLHIV had a H-TDB (18.6%). PLHIV with H-TDB were younger (p < 0.001), less frequently on current two drug antiretroviral (ARV) regimens (p = 0.01) and more frequently with plasma HIV-RNA >50 copies/mL (p = 0.04). At multivariable regression analysis, younger age (aOR 1.43, 95%CI 1.14–1.80; p = 0.002), not fully treatment satisfaction (aOR 2.19, 95%CI 1.28–3.74; p = 0.004), the need of a more accurate dialogue with treating physician (aOR 2.29, 95%CI 1.21–4.36, p = 0.01) and a self-declared lower overall Health Status (aOR 1.75, 95%CI 1.33–2.32; p = 0.002) were all associated with a H-TDB. One out of five PLHIV showed a high level of treatment and disease burden. Younger age, not fully satisfaction with ART and need of interaction with a tailored health system should be taken into consideration as correlates of treatment and disease burden in a patient-centered approach, to reduce the negative impact that it can produce on the overall perceived health status of the person.

Published
2022

6. Procalcitonin Predicts Bacterial Infection, but Not Long-Term Occurrence of Adverse Events in Patients with Acute Coronary Syndrome

Author

Pavasini, Rita, primary, Fabbri, Gioele, additional, Marchini, Federico, additional, Bianchi, Nicola, additional, Deserio, Maria Angela, additional, Sanguettoli, Federico, additional, Verardi, Filippo Maria, additional, Segala, Daniela, additional, Pompei, Graziella, additional, Tonet, Elisabetta, additional, Serenelli, Matteo, additional, Caglioni, Serena, additional, Guardigli, Gabriele, additional, Campo, Gianluca, additional, and Cultrera, Rosario, additional

Published
2022
Full Text
View/download PDF

7. Co-Infections in Critically Ill Patients with or without COVID-19: A Comparison of Clinical Microbial Culture Findings

Author

Cultrera, Rosario, primary, Barozzi, Agostino, additional, Libanore, Marco, additional, Marangoni, Elisabetta, additional, Pora, Roberto, additional, Quarta, Brunella, additional, Spadaro, Savino, additional, Ragazzi, Riccardo, additional, Marra, Anna, additional, Segala, Daniela, additional, and Volta, Carlo Alberto, additional

Published
2021
Full Text
View/download PDF

8. Switching from TDF to TAF or dual therapy (DT)-based regimens in HIV-infected individuals with viral load <= 50 copies/ml: does eGFR matter?

Author

Vergori, A, Gagliardini, R, Gianotti, N, Gori, A, Lichtner, M, Saracino, A, A De Vito, Cascio, A, A Di Biagio, A d'Arminio Monforte, Antinori, A, A Cozzi-Lepri on behalf of the ICONA Foundation Study Network, Giacometti, A., Costantini, A., Barocci, V., Angarano, G., Monno, L., Milano, E., F. Maggiolo, C. Suardi, Viale, P., Donati, V., Verucchi, G., Castelnuovo, F., Minardi, C., Quiros Roldan, E., B. Menzaghi, C. Abeli, L. Chessa, F. Pes, B. Cacopardo, B. Celesia, J. Vecchiet, K. Falasca (Chieti), A. Pan, S. Lorenzotti, Sighinolfi, L., Segala, Daniela, P. Blanc, F. Vichi, Cassola, G., Bassetti, M., Alessandrini, A., Bobbio, N., Mazzarello, G., M. Lichtner, L. Fondaco (Latina), P. Bonfanti, C. Molteni, A. Chiodera, P. Milini, G. Nunnari, G. Pellicanò, d’Arminio Monforte, A., Galli, M., Lazzarin, A., Rizzardini, G., Puoti, M., Castagna, A., Cannizzo, E. S., Moioli, M. C., Piolini, R., Bernacchia, D., Poli, A., Tincati, C., Mussini, C., Puzzolante, C., C. Migliorino, G. Lapadula, Sangiovanni, V., Borgia, G., Esposito, V., Di Flumeri, G., Gentile, I., Rizzo, V., A. M. Cattelan, S. Marinello, A. Cascio, C. Colomba, D. Francisci, E. Schiaroli, G. Parruti, F. Sozio, C. Lazzaretti, R. Corsini, Andreoni, M., Antinori, A., Cauda, R., Cristaudo, A., Vullo, V., Acinapura, R., Lamonica, S., Capozzi, M., Mondi, A., Cingolani, A., Rivano Capparuccia, M., Iaiani, G., Latini, A., Onnelli, G., Plazzi, M. M., De Girolamo, G., Vergori, A., M. Cecchetto, F. Viviani, G. Madeddu, A. De Vito, B. Rossetti, F. Montagnani, A. Franco, R. Fontana Del Vecchio, Di Giuli, C., Caramello, P., Di Perri, G., Bonora, S., Orofino, G. C., Sciandra, M., C. Tascini, A. Londer, V. Manfrin, G. Battagin, and G. Starnini, A. Ialungo

Subjects
HIV, Tenofovir alafenamide, Tenofovir disoproxil fumarate, Antiretroviral therapy, eGFR, Dual therapy, Dual therapy, Tenofovir disoproxil fumarate, eGFR, HIV, Tenofovir alafenamide, NO, Antiretroviral therapy
Published
2020

9. A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study)

Author

Mussini, Cristina, primary, Roncaglia, Enrica, additional, Borghi, Vanni, additional, Rusconi, Stefano, additional, Nozza, Silvia, additional, Cattelan, Anna Maria, additional, Segala, Daniela, additional, Bonfanti, Paolo, additional, Di Biagio, Antonio, additional, Barchi, Enrico, additional, Focà, Emanuele, additional, Degli Antoni, Anna, additional, Bonora, Stefano, additional, Francisci, Daniela, additional, Limonta, Silvia, additional, Antinori, Andrea, additional, D’Ettorre, Gabriella, additional, and Maggiolo, Franco, additional

Published
2019
Full Text
View/download PDF

11. Clin Infect Dis

Author

Shepherd, L., Ryom, L., Law, M., Petoumenos, K., Hatleberg, C. I., D'Arminio Monforte, A., Sabin, C., Bower, M., Bonnet, F., Reiss, P., De Wit, S., Pradier, C., Weber, R., El-Sadr, W., Lundgren, J., Mocroft, A., the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group, Segala, Daniela, Global Health, Infectious diseases, AII - Infectious diseases, APH - Aging & Later Life, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
0301 basic medicine, Microbiology (medical), Adult, Male, medicine.medical_specialty, medicine.medical_treatment, 030106 microbiology, Human immunodeficiency virus (HIV), HIV, smoking, smoking cessation, cancer, HIV Infections, medicine.disease_cause, smoking, NO, FR, 03 medical and health sciences, symbols.namesake, 0302 clinical medicine, Internal medicine, Neoplasms, medicine, cancer, MORPH3Eus, Humans, DAD, 030212 general & internal medicine, Poisson regression, Prospective Studies, Lung cancer, Adverse effect, Aged, Aged, 80 and over, Lung, business.industry, Incidence (epidemiology), Incidence, HIV, Cancer, Middle Aged, medicine.disease, 3. Good health, Infectious Diseases, medicine.anatomical_structure, symbols, Smoking cessation, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Female, Smoking Cessation, business
Abstract

Background Cancers are a major source of morbidity and mortality for HIV-positive persons on combination antiretroviral therapy, while the clinical benefits of smoking cessation are not well established. Methods Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex ( 5 years since stopping), current, and never smokers. Outcomes considered were any cancer, lung cancer, other smoking-related excluding lung and smoking-unrelated cancers. Adjusted incidence rate ratios (aIRR) were calculated using Poisson regression, adjusting for demographic and clinical factors. Results 35442 persons from the D:A:D study contributed 309803 person years of follow-up. At baseline, 49% of people were current smokers, 21% were ex-smokers, 30% had never smoked. Incidence of all cancers combined (N=2183) was highest

Published
2018

12. Evaluation of HIV Antiretroviral Therapy, Residual Viremia, and Immune Replacement as Possible Factors that Can Affect Systemic Inflammation

Author

Maritati, Martina, Sighinolfi, Laura, Di Nuzzo, Mariachiara, Zanotta, Nunzia, Segala, Daniela, Comar, Manola, and Contini, Carlo

Subjects
monocyte-derived chemokines (IL-8, NNRTI, Inflammation, Mann-Whitney test, IL-6, MIP-1, PI, Socio-culturale, inflammatory cytokine (IL-1, Kruskall-Wallis one-way analysis, HIV positive patients, HIV-RNA, inflammatory cytokine (IL-1, IL-6, IL-12, TNF-α), monocyte-derived chemokines (IL-8, MIP-1, MCPCD4+/CD8+, NNRTI, PI, Inflammation, Mann-Whitney test, Kruskall-Wallis one-way analysis, HIV-RNA, IL-12, TNF-α), MCPCD4+/CD8+, HIV positive patients
Published
2018

13. EVALUATION OF THE SWITCH TO A DUAL ART REGIMEN WITH LAMIVUDINE PLUS DOLUTEGRAVIR OR PROTEASE INHIBITORS IN HIV-INFECTED VIROLOGICALLY SUPPRESSED PATIENTS. A REAL LIFE EXPERIENCE

Author

Maritati, Martina, Trentini, Alessandro, Lo Menzo, Sara, Segala, Daniela, Contini, Carlo, and Sighinolfi, Laura

Subjects
AIDS, dolutegravir (DTG), lamivudine (3TC), lamivudine + protease inhibitors (PI), semplification, Socio-culturale, AIDS, ART, semplification, lamivudine (3TC), dolutegravir (DTG), lamivudine + protease inhibitors (PI), ART
Published
2017

14. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients

Author

Taramasso, Lucia, primary, Di Biagio, Antonio, additional, Bovis, Francesca, additional, Nicolini, Laura Ambra, additional, Antinori, Andrea, additional, Milazzo, Laura, additional, Sollima, Salvatore, additional, Gubertini, Guido, additional, Niero, Fosca, additional, Saracino, Annalisa, additional, Bruno, Raffaele, additional, Borghi, Vanni, additional, Montagnani, Francesca, additional, Cattelan, Annamaria, additional, Hasson, Hamid, additional, Taliani, Gloria, additional, D’Arminio Monforte, Antonella, additional, Mastroianni, Claudio, additional, Di Perri, Giovanni, additional, Bigoni, Sara, additional, Puoti, Massimo, additional, Spinetti, Angiola, additional, Gori, Andrea, additional, Boffa, Nicola, additional, Cacopardo, Bruno, additional, Giacometti, Andrea, additional, Parruti, Giustino, additional, Vullo, Vincenzo, additional, Chirianni, Antonio, additional, Teti, Elisabetta, additional, Pasquazzi, Caterina, additional, Segala, Daniela, additional, and Andreoni, Massimo, additional

Published
2018
Full Text
View/download PDF

15. INTERVENTO DI FORMAZIONE/INFORMAZIONE CIRCA LE MODALITÀ DI TRASMISSIONE/PREVENZIONE DI MALATTIE SESSUALMENTE TRASMISSIBILI (SDTS) AD UNA POPOLAZIONE DI MIGRANTI RICHIEDENTI ASILO/RIFUGIATI CON OFFERTA ATTIVA DEL TEST HIV. STUDIO PILOTA NELLA PROVINCIA DI FERRARA. DATI PRELIMINARI

Author

Segala, Daniela, Calacoci, Manu, Tsucalas, Fabrizio, Libanore, Marco, Contini, Carlo, and Sighinolfi, Laura I.

Subjects
HBV, vaccinazione anti-HBV, Socio-culturale, HIV+, HBV, HBsAg+, anti-HBs+, vaccinazione anti-HBV, HIV e STD, anti-HBs+, HIV+, HBsAg+, HIV e STD
Published
2016

16. Health education and HIV test offer in a population of refugees and asylum seekers: an experience in Ferrara area

Author

Segala, Daniela, Contini, Carlo, Libanore, Marco, and Sighiniolfi, Laura

Subjects
STDs, Migrants, refugees and asylum seekers, Sexually transmitted disease, STDs, HIV/AIDS patients, HBV infection, Camelot association, access to public health service and HIV/STDs test, access to public health service and HIV/STDs test, Camelot association, Socio-culturale, Sexually transmitted disease, HIV/AIDS patients, refugees and asylum seekers, Migrants, HBV infection
Published
2016

17. Persistent HIV low-level viremia and cardiovascular risk

Author

Silvia, Costarelli, Davide, Bernasconi, Giuseppe, Lapadula, Francesco, Castelli, Salvatore, Casari, Franco, Maggiolo, Antonella, Grisolia, Annalisa, Saracino, Gian Maria Baldin, Massimo, Dipietro, Segala, Daniela, Chiara, Fornabaio, and Nicola Mazzini and Andrea Gori for the Italian MASTER cohort

Subjects
NO
Published
2015

19. GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trial

Author

Capone, Stefania, Fusco, Francesco M., Milleri, Stefano, Borrè, Silvio, Carbonara, Sergio, Lo Caputo, Sergio, Leone, Sebastiano, Gori, Giovanni, Maggi, Paolo, Cascio, Antonio, Lichtner, Miriam, Cauda, Roberto, Dal Zoppo, Sarah, Cossu, Maria V., Gori, Andrea, Roda, Silvia, Confalonieri, Paola, Bonora, Stefano, Missale, Gabriele, Codeluppi, Mauro, Mezzaroma, Ivano, Capici, Serena, Pontali, Emanuele, Libanore, Marco, Diani, Augusta, Lanini, Simone, Battella, Simone, Contino, Alessandra M., Piano Mortari, Eva, Genova, Francesco, Parente, Gessica, Dragonetti, Rosella, Colloca, Stefano, Visani, Luigi, Iannacone, Claudio, Carsetti, Rita, Folgori, Antonella, Camerini, Roberto, Ziviani, Luigi, Malescio, Feliciana, Turrini, Irene, Lawlor, Rita, Romano, Annamaria, Nunziata, Mariagrazia, Armato, Salvatore, Mazzeo, Nicole, Carleo, Maria Aurora, Dell’Isola, Chiara, Pisapia, Raffaella, Pontarelli, Agostina, Olivani, Andrea, Grasselli, Sara, Laccabue, Diletta, Leoni, Maria Cristina, Paolillo, Franco, Mancini, Annalisa, Ruaro, Barbara, Confalonieri, Marco, Salton, Francesco, Mancarella, Giulia, Marocco, Raffaella, De Masi, Margherita, Belvisi, Valeria, Lamonica, Silvia, Cingolani, Antonella, Seguiti, Cristina, Brambilla, Paola, Ferraresi, Alice, Lupi, Matteo, Ludovisi, Serena, Renisi, Giulia, Massafra, Roberta, Pellicciotta, Martina, Armiento, Luciana, Vimercati, Stefania, Piacenza, Mariagrazia, Bonfanti, Paolo, Columpsi, Paola, Cazzaniga, Marina Elena, Rovelli, Cristina, Ceresini, Mariaelena, Previtali, Letizia, Trentini, Laura, Alcantarini, Chiara, Rugge, Walter, Biffi, Stefano, Poletti, Federica, Rostagno, Roberto, Moglia, Roberta, De Negri, Ferdinando, Fini, Elisabetta, Cangialosi, Alice, Bruno, Serena Rita, Rizzo, Marianna, Niglio, Mariangela, Stritto, Anna Dello, Matano, Alfredo, Petruzziello, Arnolfo, Valsecchi, Pietro, Pieri, Teresa, Altamura, Mauro, Calamo, Angela, Giannelli, Anna, Menolascina, Stefania, Di Bari, Silvia, Mauro, Vera, Aronica, Raissa, Segala, Daniela, Cultrera, Rosario, Sighinolfi, Laura, Abbott, Michelle, Gizzi, Andrea, Marascia, Federica Guida, Valenti, Giacomo, Feasi, Marcello, Bobbio, Nicoletta, Del Puente, Filippo, Nicosia, Alfredo, Frascà, Martina, Mazzoleni, Miriam, Garofalo, Nadia, Ammendola, Virginia, Grazioli, Fabiana, Napolitano, Federico, Vitelli, Alessandra, and Marcellini, Valentina

Abstract

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic and heterologous immunization approaches implemented worldwide for booster doses call for diversified vaccine portfolios. GRAd-COV2 is a gorilla adenovirus-based COVID-19 vaccine candidate encoding prefusion-stabilized spike. The safety and immunogenicity of GRAd-COV2 is evaluated in a dose- and regimen-finding phase 2 trial (COVITAR study, ClinicalTrials.gov: NCT04791423) whereby 917 eligible participants are randomized to receive a single intramuscular GRAd-COV2 administration followed by placebo, or two vaccine injections, or two doses of placebo, spaced over 3 weeks. Here, we report that GRAd-COV2 is well tolerated and induces robust immune responses after a single immunization; a second administration increases binding and neutralizing antibody titers. Potent, variant of concern (VOC) cross-reactive spike-specific T cell response peaks after the first dose and is characterized by high frequencies of CD8s. T cells maintain immediate effector functions and high proliferative potential over time. Thus, GRAd vector is a valuable platform for genetic vaccine development, especially when robust CD8 response is needed.

Published
2023
Full Text
View/download PDF

20. Rate and Determinants of Residual Viremia in Multidrug-Experienced Patients Successfully Treated with Raltegravir-Based Regimens

Author

Baroncelli, Silvia, primary, Pirillo, Maria Franca, additional, Galluzzo, Clementina Maria, additional, Antoni, Anna Degli, additional, Ladisa, Nicoletta, additional, Francisci, Daniela, additional, d'Ettorre, Gabriella, additional, Segala, Daniela, additional, Vivarelli, Angela, additional, Sozio, Federica, additional, Cirioni, Oscar, additional, Weimer, Liliana Elena, additional, Fragola, Vincenzo, additional, Parruti, Giustino, additional, and Floridia, Marco, additional

Published
2015
Full Text
View/download PDF

21. The prognostic role of systemic inflammatory markers on HIV-infected patients with non-Hodgkin lymphoma, a multicenter cohort study.

Author

Raffetti, Elena, Donato, Francesco, Castelnuovo, Filippo, Ladisa, Nicoletta, Paraninfo, Giuseppe, Di Filippo, Elisa, Segala, Daniela, Cologni, Giuliana, Bandera, Alessandra, Zacchi, Fabio, Digiambenedetto, Simona, Di Pietro, Massimo, Castelli, Francesco, and Cohort-Roldan, Eugenia

Subjects
INFLAMMATION, HIV-positive persons, BIOMARKERS, HODGKIN'S disease, NEUTROPHILS, LYMPHOCYTES
Abstract

Background: The systemic inflammatory response has been postulated as having prognostic significance in a wide range of different cancer types. We aimed to assess the prognostic role of inflammatory markers on survival in HIVinfected patients with Non-Hodgkin Lymphoma (NHL), and to compute a prognostic score based on inflammatory biomarkers. Methods: We evaluated data on HIV patients with NLH diagnosis between 1998 and 2012 in a HIV Italian Cohort. Using Cox proportional regression model, we assessed the prognostic role of Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), Glasgow Prognostic Score (GPS), modified Glasgow Prognostic Score (mGPS), Prognostic Index (PI), and Prognostic Nutritional Index (PNI). We also computed a risk score equation, assigning patients to a derivation and a validation sample. The area under the curve (AUC) was use to evaluate the predictive ability of this score. Results: 215 non-Hodgkin lymphoma cases (80.0% males) with a mean age of 43.2 years were included. Deaths were observed in 98 (45.6%) patients during a median follow up of 5 years. GPS, mGPS, PI and PNI were independently associated with risk of death. We also computed a mortality risk score which included PNI and occurrence of an AIDS event within six months from NHL diagnosis. The AUCs were 0.69 (95% CI 0.58 to 0.81) and 0.69 (95% CI 0.57 to 0.81) at 3 and 5 years of the follow-up, respectively. Conclusions: GPS, mGPS, PI and PNI are independent prognostic factors for survival of HIV patients with NHL. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

23. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.

Author

Raffetti, Elena, Albini, Laura, Gotti, Daria, Segala, Daniela, Maggiolo, Franco, di Filippo, Elisa, Saracino, Annalisa, Ladisa, Nicoletta, Lapadula, Giuseppe, Fornabaio, Chiara, Castelnuovo, Filippo, Casari, Salvatore, Fabbiani, Massimiliano, Pierotti, Piera, Donato, Francesco, and Quiros-Roldan, Eugenia

Subjects
HIV-positive persons, MEDICAL centers, ETIOLOGY of diseases, COMPARATIVE studies, COHORT analysis
Abstract

Background: We aimed to assess cancer incidence and mortality for all-causes and factors related to risk of death in an Italian cohort of HIV infected unselected patients as compared to the general population. Methods: We conducted a retrospective (1986-2012) cohort study on 16 268 HIV infected patients enrolled in the MASTER cohort. The standardized incidence ratios (SIRs) and standardized mortality ratios (SMRs) were computed using cancer incidence rates of Italian Cancer Registries and official national data for overall mortality. The risk factors for death from all causes were assessed using Poisson regression models. Results: 1,195 cancer cases were diagnosed from 1986 to 2012: 700 AIDS-defining-cancers (ADCs) and 495 non-AIDS-defining-cancers (NADCs). ADC incidence was much higher than the Italian population (SIR = 30.8, 95% confidence interval 27.9-34.0) whereas NADC incidence was similar to the general population (SIR = 0.9, 95% CI 0.8-1.1). The SMR for all causes was 11.6 (11.1-12.0) in the period, and it decreased over time, mainly after 1996, up to 3.53 (2.5-4.8) in 2012. Male gender, year of enrolment before 1993, older age at enrolment, intravenous drug use, low CD4 cell count, AIDS event, cancer occurrence and the absence of antiretroviral therapy were all associated independently with risk of death. Conclusions: In HIV infected patients, ADC but not NADC incidence rates were higher than the general population. Although overall mortality in HIV infected subjects decreased over time, it is about three-fold higher than the general population at present. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

26. Disease Progression in HIV Late Presenters: the Role of HIV Clinical Indicator Diseases Prior to HIV Diagnosis

Author

Laura Sighinolfi, Viola Guardigni, Mario Luca Morieri, Daniela Segala, Guardigni, Viola, Morieri, Mario Luca, Segala, Daniela, and Sighinolfi, Laura

Subjects
Adult, Male, medicine.medical_specialty, Delayed Diagnosis, Disease progression, Early diagnosis, HIV/AIDS, Late presentation, Missed opportunities, Population, HIV Infections, NO, Hospitals, University, Acquired immunodeficiency syndrome (AIDS), Virology, Internal medicine, Humans, Medicine, HIV Infection, education, Retrospective Studies, education.field_of_study, business.industry, Proportional hazards model, Confounding, Hazard ratio, Delayed Diagnosi, virus diseases, Retrospective cohort study, Middle Aged, medicine.disease, Infectious Diseases, Italy, Immunology, Coinfection, Disease Progression, Female, Observational study, business
Abstract

Background: Late diagnosis represents a major challenge in the control of HIV epidemics. The rate of disease progression is higher among late presenters. In Europe, HIV Clinical Indicator Diseases (CIDs) have been proposed to improve early diagnosis. Objectives: Our observational study evaluated the presence of these HIV CIDs prior to HIV diagnosis among a population of late presenters and assessed its correlation to disease progression. Method: A retrospective cohort study was conducted in HIV late presenters diagnosed from 2007 to 2013 at University Hospital of Ferrara (Italy). Hazard Ratios (H.R.s) for disease progression (new AIDS-events and death) were estimated by Cox proportional hazard model. Results: We analysed 77 patients and we found that those with CIDs prior to HIV diagnosis (22%) had a 2.8 fold higher rate of disease progression compared to those without HIV CIDs (H.R. 2.82; 95% CI 1.21-6.53; P 0.02). Other factors associated with disease progression were AIDS presentation, HCV coinfection and Haemoglobin levels, with H.R.s of 3.14 (95%CI 1.23-7.99), 2.95 (95% CI 1.14-7.61) and 0.74 (95% CI 0.60-0.91), respectively. Conclusion: HIV CIDs confer a higher risk for disease progression even after adjustment for these confounding factors. Evaluation of previous HIV CIDs at HIV diagnosis could be an additional tool to identify and better manage HIV late presenters with higher risks of disease progression.

Published
2016

27. Entheseal involvement in asymptomatic human immunodeficiency virus infected patients: preliminary results of a clinical and ultrasonographic study.

Author

Ciancio G, Sighinolfi L, Furini F, Segala D, Farina I, Galuppi E, De Stefani E, Simone L, Boccia S, Grilli A, Pazzi P, Libanore M, Contini C, and Govoni M

Subjects
Adult, Asymptomatic Diseases, Case-Control Studies, Enthesopathy epidemiology, Enthesopathy virology, Female, HIV Infections epidemiology, HIV Infections virology, Humans, Italy epidemiology, Male, Middle Aged, Predictive Value of Tests, Preliminary Data, Prevalence, Spondylarthritis epidemiology, Spondylarthritis virology, Synovitis epidemiology, Synovitis virology, Enthesopathy diagnostic imaging, HIV Infections diagnostic imaging, Joints diagnostic imaging, Spondylarthritis diagnostic imaging, Synovitis diagnostic imaging, Ultrasonography, Doppler
Abstract

Objectives: As a strong association between human immunodeficiency virus (HIV) infection and spondyloarthritis (SpA) has been hypothesised, our main objective was to explore by power Doppler ultrasonography (PDUS) the presence of subclinical enthesitis in asymptomatic HIV patients. The presence of subclinical synovitis was also evaluated., Methods: Consecutive asymptomatic HIV patients were studied and compared with asymptomatic HCV patients and healthy controls (HC). All subjects underwent a clinical and PDUS bilateral examination of the following entheses and joints: epicondyle, quadriceps, patellar, Achilles and plantar fascia; wrists, II and III metacarpo-phalangeal, knee and ankle., Results: Twenty-nine HIV, 32 HCV and 25 HC were recruited; 1.032 entheses and 860 joints were examined. Clinical diagnosis of enthesitis was made in 10.3% HIV patients, 6.2% HCV patients (p=0.66) and none HC (p=0.24). PDUS enthesitis was found in 72.4% HIV, 28.1% HCV (p=0.0008) and 12% HC (p<0.0001). Clinical diagnosis of synovitis was made in 3.4% HIV patients, 9.3% HCV patients (p=0.61) and none HC (p=1). PDUS abnormalities were documented in 24.1% HIV patients, 71.8% HCV patients (p=0.0003) and none HC (p=0.0001). In detecting enthesitis and synovitis, PDUS was more sensitive than clinical examination both in HIV and HCV patients., Conclusions: Our preliminary study shows the high frequency of PDUS enthesitis in asymptomatic HIV patients, which highlights the close link between HIV and SpA. Further studies are desirable on a larger number of HIV patients to confirm these results. PDUS proved to be more sensitive than clinical examination in detecting subclinical involvement of entheses and joints.

Published
2018

28. Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program.

Author

Massimo A, Teti E, Antinori A, Milazzoi L, Sollima S, Rizzardini G, Di Biagio A, Saracino A, Bruno R, Borghi V, De Luca A, Cattelan A, Hasson H, Taliani G, Monforte AD, Mastroianni CM, Di Perri G, Bigoni S, Puoti M, Spinetti A, Gori A, Boffa N, Bruno C, Giacometti A, Parruti G, Vullo V, Chirianni A, Pennica A, Pasquazzi C, Segala D, and Sarmati L

Abstract

Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV co-infected patients participating in an Italian compassionate-use program of ombitasvir/paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV)., (© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results